Framingham, MA, United States of America

John Memmott

USPTO Granted Patents = 14 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 86(Granted Patents)

Company Filing History:

Abb Vie Deutschland Gmbh & Co. Kg

patents

1 out of 4,177

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2012-2018

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10106602 - Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof (2018-10-23),

2. 9803009 - Immunobinders directed against TNF (2017-10-31),

3. 9663587 - IL-17 binding proteins (2017-05-30),

4. 9655964 - Bispecific antibodies directed against TNF-α and IL-17 (2017-05-23),

5. 9481736 - IL-17 binding proteins (2016-11-01),

6. 9481735 - IL-17 binding proteins (2016-11-01),

7. 9365643 - Antibodies that bind to repulsive guidance molecule A (RGMA) (2016-06-14),

8. 9102722 - Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration (2015-08-11),

9. 8999331 - Immunobinders directed against sclerostin (2015-04-07),

10. 8916504 - Methods of RNA display (2014-12-23),

11. 8835610 - IL-17 binding proteins (2014-09-16),

12. 8779101 - IL-17 binding proteins (2014-07-15),

13. 8404445 - Antibody libraries (2013-03-26),

14. 8324350 - Dual-specific IL-1α/IL-1β antibodies (2012-12-04),

Title: The Innovative Mind of John Memmott

In the realm of biotechnology, John Memmott stands out as a prominent inventor based in Framingham, MA. His contributions to the field are marked by a significant number of patents, showcasing his commitment to advancing medical science through innovative solutions.

Latest Patents

John Memmott holds 14 patents, with his latest innovations focusing on critical medical applications. One of his noteworthy patents is the development of isolated monoclonal anti-repulsive guidance molecule A antibodies. This invention offers methods for utilizing these antibodies to treat and diagnose neurite degenerative diseases and disorders. Another significant patent involves immunobinders directed against tumor necrosis factor-alpha (TNF-α). This innovation includes isolated binding proteins that interact with TNF-α and provides various therapeutic and diagnostic methods utilizing these antibodies.

Career Highlights

Throughout his career, John has been affiliated with prominent companies, including AbbVie Inc. and AbbVie Deutschland GmbH & Co. KG. His work in these organizations has not only reinforced his expertise but also facilitated the development of groundbreaking inventions.

Collaborations

Collaboration has been a key element of John's success. He has worked alongside talented professionals such as Yuliya Kutskova and Chung-Ming Hsieh, contributing to an environment of shared knowledge and innovation.

Conclusion

John Memmott's contributions to biotechnology underscore the importance of innovation in addressing complex medical challenges. His extensive portfolio of patents highlights his role as a forward-thinking inventor, dedicated to improving healthcare through his groundbreaking discoveries.

This text is generated by artificial intelligence and may not be accurate.